Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388963%3A_____%2F20%3A00531686" target="_blank" >RIV/61388963:_____/20:00531686 - isvavai.cz</a>
Alternative codes found
RIV/61989592:15110/20:73605861
Result on the web
<a href="https://worldwide.espacenet.com/publicationDetails/originalDocument?CC=JP&NR=6650074B2&KC=B2&FT=D&ND=4&date=20200219&DB=&locale=en_EP" target="_blank" >https://worldwide.espacenet.com/publicationDetails/originalDocument?CC=JP&NR=6650074B2&KC=B2&FT=D&ND=4&date=20200219&DB=&locale=en_EP</a>
DOI - Digital Object Identifier
—
Alternative languages
Result language
—
Original language name
治療に使用するための、置換チェノピロロピリミジンリボヌクレオシド
Original language description
本発明は、一般式Ｉの置換チエノピロロピリミジンリボヌクレオシドの新しい群を提供し、ここでＲは請求項で定義される。 本発明の化合物は、好ましくは様々な組織遺伝学的起源の腫瘍を含む広範囲の疾患の癌細胞株に対して、強力な細胞増殖抑制および細胞毒性活性を示す。
Czech name
—
Czech description
—
Classification
Type
P - Patent
CEP classification
—
OECD FORD branch
30107 - Medicinal chemistry
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Patent/design ID
JP6650074
Publisher
JP001 -
Publisher name
Japan Patent Office (JPO)
Place of publication
Tokyo
Publication country
JP - JAPAN
Date of acceptance
Feb 19, 2020
Owner name
Ústav organické chemie a biochemie AV ČR, v. v. i. - Univerzita Palackého v Olomouci
Method of use
A - Výsledek využívá pouze poskytovatel
Usage type
A - K využití výsledku jiným subjektem je vždy nutné nabytí licence